As TDP-43 cytoplasmic aggregates are observed in ∼95% of ALS and tau-negative FTD, the understanding of the mechanisms contributing to the build-up of TDP-43 proteinopathy is critical in unravelling disease development and holds the key to developing effective therapeutic strategies. The gene discussed is TARDBP; the disease is frontotemporal dementia.